LAUSANNE and VILLARS-SUR-GLÂNE, Switzerland, May 15, 2012 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm) and Vifor Pharma announce the signing of an exclusive agreement

PARSIPPANY, N.J., Sept.

WASHINGTON, May 16, 2011 /PRNewswire/ -- A poster entitled, "Time to Progression in Patients with Prostate Cancer: A Comparison of Continuous Degarelix versus Degarelix Following Leuprolide Treatment," is being presented at the American Urological Association 2011 meeting by E.

NEW YORK, Oct. 27 /PRNewswire/ -- Drugs, known as gonadotropin-releasing hormone (GnRH) agonists, may raise diabetes and heart risk and, as a result, now need new warnings. U.S.

SAN FRANCISCO, June 1 /PRNewswire/ -- FIRMAGON® (degarelix for injection) resulted in fast, long-term suppression of testosterone in prostate cancer patients, without an initial testosterone surge or microsurge, and rapidly reduced prostate-specific antigen (PSA) levels, according to a review of data presented here today at the AUA 2010 annual meeting by Dr.